UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000027026
Receipt number R000030985
Scientific Title Oral beclomethasone dipropionate treatment for gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Date of disclosure of the study information 2017/04/17
Last modified on 2019/04/24 20:00:26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Oral beclomethasone dipropionate treatment for gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Acronym

Oral beclomethasone dipropionate treatment for gastrointestinal GVHD after allo-HSCT

Scientific Title

Oral beclomethasone dipropionate treatment for gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Scientific Title:Acronym

Oral beclomethasone dipropionate treatment for gastrointestinal GVHD after allo-HSCT

Region

Japan


Condition

Condition

Patients with symptoms of acute gastrointestinal GVHD after allo-HSCT

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Treatment for gastrointestinal GVHD after allo-HSCT

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Whether beclomethasone improve GI GVHD grade or reduce the need for systemic glucocorticoid treatment, at two weeks after administration.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

administration of oral beclomethasone
1-2capx4 /day; 4-8mg/day
about 50 days

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Who are admitted to our hospital for the purpose of allogeneic hematopoietic stem cell transplantation , and cases in which data can be collected for research.

Key exclusion criteria

1. Cases who can not be collected data.
2. Patients whose research managers judged inappropriate as subjects.
3. Patients who had requested refusal to investigate.

Target sample size

5


Research contact person

Name of lead principal investigator

1st name Junji
Middle name
Last name Tanaka

Organization

Tokyo Women's Medical University

Division name

Department of Hematology

Zip code

162-8666

Address

8-1, Kawada-cho, Shinjyuku-ku, Tokyo, Japan

TEL

03-3353-8111

Email

jutanaka@twmu.ac.jp


Public contact

Name of contact person

1st name Norina
Middle name
Last name Tanaka

Organization

Tokyo Women's Medical University

Division name

Department of Hematology

Zip code

162-8666

Address

8-1, Kawada-cho, Shinjyuku-ku, Tokyo, Japan

TEL

03-3353-8111

Homepage URL


Email

tanaka.norina@twmu.ac.jp


Sponsor or person

Institute

Tokyo Women's Medical University, Department of Hematology

Institute

Department

Personal name



Funding Source

Organization

Tokyo Women's Medical University, Department of Hematology

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Tokyo Women's Medical University, IRB

Address

8-1, Kawada-cho, Shinjyuku-ku, Tokyo, Japan

Tel

03-3353-8111

Email

krinri.bm@twmu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 04 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 11 Month 22 Day

Date of IRB

2016 Year 11 Month 22 Day

Anticipated trial start date

2017 Year 04 Month 04 Day

Last follow-up date

2019 Year 01 Month 18 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 04 Month 17 Day

Last modified on

2019 Year 04 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030985


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name